Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.75 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.75 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 7/20 | 0.50 |
| ▸ | KDM5C | P41229 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | KDM6B | O15054 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL27584447 | 0.87 | EGLN1 (0.82) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL30575212 | 0.87 | EGLN1 (0.82) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL3628497 | 0.87 | EGLN1 (0.82) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL1331200 | 0.87 | — | — | |
| Succinic Acid SCHEMBL21867134 | 0.87 | LMNA (1.00) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL829 | 0.87 | — | — | |
| Succinic Acid SCHEMBL4269130 | 0.87 | LMNA (1.00) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL4269135 | 0.87 | LMNA (1.00) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL24696 | 0.87 | LMNA (1.00) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL3799615 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110723910-B | Cell culture material for controlling cell adhesion and cell detachment and preparation method thereof | 东南大学 | 2021-12-07 | — | — | CN | claimed |
| CN-116354904-B | Quetiapine derivative hapten, antigen, anti-quetiapine antibody and application thereof | 北京丹大生物技术有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116354904-A | Quetiapine derivative hapten, antigen, anti-quetiapine antibody and application thereof | 北京丹大生物技术有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115845152-A | Medical instrument | 元心科技(深圳)有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| CN-109803693-B | Medical instrument | 元心科技(深圳)有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| CN-114096525-A | Biaryl compounds, pharmaceutical compositions containing them, processes for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113773251-A | Anilines useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| CN-104968661-B | Substituted amino azole as plant growth regulator | 先正达参股股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-9650380-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9512119-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20150191463-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2878594-A1 | DIFLUOROMETHYLENE COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2015-06-03 | — | — | EP | disclosed |
| CN-1744892-A | Breast cancer resistance protein (BCRP) inhibitor | YAKULT HONSHA KK (JP) | 2006-03-08 | — | — | CN | disclosed |
| US-6071960-A | FOR TREATMENT OF DISEASES CAUSED BY OR RESULTING IN METABOLIC DYSFUNCTION AND/OR ENERGY DEPRIVATION, SUCH AS DIABETES, ACUTE STARVATION, ENDOTOXEMIA, SEPSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AND MULTIPLE ORGEN DYSFUNCTION SYNDROME | Leo Pharmaceuticals Products Ltd. A/S (L.o slashed.vens kemiske Fabrik Produktion-saktieselskab (DK) | 2000-06-06 | — | — | US | disclosed |
| EP-0912491-A1 | POLYOL SUCCINATES AND THEIR PHARMACEUTICAL FORMULATION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997047584-A1 | POLYOL SUCCINATES AND THEIR PHARMACEUTICAL FORMULATION | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | XDH, URB2, MNAT1 | EGLN1 1566/4885LMNA 2671/4885ALKBH5 1244/4885 |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | EGLN1 993/4885LMNA 2963/4885ALKBH5 1331/4885 |
| US-20150191463-A1 | DIFLUOROMETHYLENE COMPOUND | XDH, SULT1A1, RFT1 | EGLN1 1616/4885LMNA 3114/4885ALKBH5 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.